循环核小体、HMGB1 和 sRAGE 与前列腺癌诊断的相关性。
Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.
机构信息
Department of Clinical Pathology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal;
Department of Laboratory Medicine, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
出版信息
In Vivo. 2021 Jul-Aug;35(4):2207-2212. doi: 10.21873/invivo.12492.
BACKGROUND/AIM: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa.
PATIENTS AND METHODS
A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays.
RESULTS
There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180).
CONCLUSION
In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.
背景/目的：逃避细胞死亡发生在前列腺癌（PCa）中。我们验证了细胞死亡标志物的血清水平是否在 PCa 中有诊断价值。
患者和方法
共纳入 233 名计划进行前列腺活检的男性[前列腺特异性抗原（PSA）水平：2-10ng/ml]。通过酶免疫分析法分析血清核小体、含有 H3 组蛋白（H3）的核小体、高迁移率族蛋白 B1（HMGB1）和可溶性晚期糖基化终产物受体（sRAGE）。
结果
有或没有 PCa 或临床显著 PCa（csPCa）的患者之间核小体、H3 和 sRAGE 水平无差异（p>0.05）。HMGB1 在 PCa 患者中的水平较低（p=0.023），是 PCa 的预测因子（p=0.047），但不是 csPCa 的预测因子（p=0.180）。
结论
在 PSA 水平在 2-10ng/ml 之间的临界患者中，HMGB1 对整体 PCa 检测具有一定的诊断价值，但对 csPCa 没有预测价值。核小体、H3 和 sRAGE 不能区分 PCa 或 csPCa 与对照组。
Zotero 插件